Heptares, AstraZeneca in GPCR discovery deal

Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to discover and develop therapeutics against GPCR targets in CNS/pain, cardiovascular/metabolic ...